John Cooper
About John Cooper
John Cooper is the Vice President of CMC at KalVista Pharmaceuticals, Inc., where he has worked since 2022. He has a background in chemistry and extensive experience in the pharmaceutical industry, having held various leadership roles at companies such as Pfizer and UCB Pharma.
Current Role at KalVista Pharmaceuticals
John Cooper serves as the Vice President of CMC at KalVista Pharmaceuticals, Inc. since 2022. His role involves overseeing the Chemistry, Manufacturing, and Controls (CMC) aspects of the company's pharmaceutical development processes. He operates from the Salisbury location in England, United Kingdom. His experience in this position builds on his previous role as Senior Director, CMC at the same company from 2019 to 2022.
Previous Experience in the Pharmaceutical Industry
Prior to his current position, John Cooper worked at several notable pharmaceutical companies. He was the Director of Pharmaceutics & Process Technology at Patheon from 2018 to 2019. Before that, he held the position of Senior Principal Scientist at UCB Pharma from 2004 to 2008. He also served as the Analytical and Formulations Lead at Pfizer from 2008 to 2011. His extensive background includes managing outsourced activities within the pharmaceutical sector.
Education and Academic Background
John Cooper completed his Bachelor of Science with Honours in Chemistry at the University of Strathclyde from 1985 to 1990. He later pursued a Master of Science in Analytical Chemistry at Anglia Ruskin University from 1995 to 1998. His academic qualifications provide a strong foundation for his expertise in the pharmaceutical industry.
Project Management Certification
John Cooper is a registered PRINCE2 Practitioner, which indicates his proficiency in project management methodologies. This certification reflects his capability to manage projects effectively within the pharmaceutical industry, ensuring that processes align with organizational goals.
Citizenship
John Cooper holds dual citizenship in the United Kingdom and Canada. This status may provide him with diverse opportunities and perspectives within the global pharmaceutical landscape.